JP2013518881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518881A5 JP2013518881A5 JP2012551994A JP2012551994A JP2013518881A5 JP 2013518881 A5 JP2013518881 A5 JP 2013518881A5 JP 2012551994 A JP2012551994 A JP 2012551994A JP 2012551994 A JP2012551994 A JP 2012551994A JP 2013518881 A5 JP2013518881 A5 JP 2013518881A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyrrolo
- pyridin
- benzamide
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 72
- 125000000753 cycloalkyl group Chemical group 0.000 claims 23
- 125000005842 heteroatom Chemical group 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000001475 halogen functional group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- -1 halo (C 1-6 ) alkoxy Chemical group 0.000 claims 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 230000036407 pain Effects 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 7
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 3
- 208000010444 Acidosis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 208000007976 Ketosis Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027417 Metabolic acidosis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029350 Neurotoxicity Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000001848 dysentery Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 2
- 230000004140 ketosis Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000003880 negative regulation of appetite Effects 0.000 claims 2
- 230000002232 neuromuscular Effects 0.000 claims 2
- 231100000228 neurotoxicity Toxicity 0.000 claims 2
- 230000007135 neurotoxicity Effects 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 230000008736 traumatic injury Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- FMRRDKHCBMCCHR-FQEVSTJZSA-N 4-[(2r)-1,2-dihydroxypropan-2-yl]-n-(1-ethyl-3-methylpyrrolo[3,2-c]pyridin-6-yl)benzamide Chemical compound C1=C2N(CC)C=C(C)C2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C=C1 FMRRDKHCBMCCHR-FQEVSTJZSA-N 0.000 claims 1
- QJLUVUWHGZTKRP-FQEVSTJZSA-N 4-[(2r)-1,2-dihydroxypropan-2-yl]-n-(1-ethylpyrrolo[3,2-c]pyridin-6-yl)-3-methylbenzamide Chemical compound C1=C2N(CC)C=CC2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C(C)=C1 QJLUVUWHGZTKRP-FQEVSTJZSA-N 0.000 claims 1
- LNRQIJNRHFDHNW-IBGZPJMESA-N 4-[(2r)-1,2-dihydroxypropan-2-yl]-n-(1-ethylpyrrolo[3,2-c]pyridin-6-yl)benzamide Chemical compound C1=C2N(CC)C=CC2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C=C1 LNRQIJNRHFDHNW-IBGZPJMESA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KTWLWSBHHAXVSH-FQEVSTJZSA-N n-(1-cyclopropylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=CC([C@@](O)(CO)C)=CC=C1C(=O)NC(N=C1)=CC2=C1C=CN2C1CC1 KTWLWSBHHAXVSH-FQEVSTJZSA-N 0.000 claims 1
- AGPTUNRVLHLJTR-FQEVSTJZSA-N n-(3-bromo-1-cyclopropylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=CC([C@@](O)(CO)C)=CC=C1C(=O)NC(N=C1)=CC2=C1C(Br)=CN2C1CC1 AGPTUNRVLHLJTR-FQEVSTJZSA-N 0.000 claims 1
- GNDQKBUOIUXIMO-IBGZPJMESA-N n-(3-bromo-1-ethylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=C2N(CC)C=C(Br)C2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C=C1 GNDQKBUOIUXIMO-IBGZPJMESA-N 0.000 claims 1
- DPUUISXAWAXOMR-SFHVURJKSA-N n-(3-bromo-1-methylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=C2N(C)C=C(Br)C2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C=C1 DPUUISXAWAXOMR-SFHVURJKSA-N 0.000 claims 1
- NLZWRGUKMSYZPS-UHFFFAOYSA-N n-(3-chloro-1-cyclopropylpyrrolo[3,2-c]pyridin-6-yl)-4-(1-hydroxy-2-methylpropan-2-yl)benzamide Chemical compound C1=CC(C(C)(CO)C)=CC=C1C(=O)NC(N=C1)=CC2=C1C(Cl)=CN2C1CC1 NLZWRGUKMSYZPS-UHFFFAOYSA-N 0.000 claims 1
- OJYSZUABAXPGIE-FQEVSTJZSA-N n-(3-chloro-1-cyclopropylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=CC([C@@](O)(CO)C)=CC=C1C(=O)NC(N=C1)=CC2=C1C(Cl)=CN2C1CC1 OJYSZUABAXPGIE-FQEVSTJZSA-N 0.000 claims 1
- YNCUMYDOPLRRHQ-FQEVSTJZSA-N n-(3-chloro-1-ethylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]-3-methylbenzamide Chemical compound C1=C2N(CC)C=C(Cl)C2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C(C)=C1 YNCUMYDOPLRRHQ-FQEVSTJZSA-N 0.000 claims 1
- RFXCQMPYISFHBQ-IBGZPJMESA-N n-(3-chloro-1-ethylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=C2N(CC)C=C(Cl)C2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C=C1 RFXCQMPYISFHBQ-IBGZPJMESA-N 0.000 claims 1
- RFXCQMPYISFHBQ-LJQANCHMSA-N n-(3-chloro-1-ethylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2s)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=C2N(CC)C=C(Cl)C2=CN=C1NC(=O)C1=CC=C([C@](C)(O)CO)C=C1 RFXCQMPYISFHBQ-LJQANCHMSA-N 0.000 claims 1
- HZDQWXQRWFHBHB-UHFFFAOYSA-N n-(3-chloro-1-methylpyrrolo[3,2-c]pyridin-6-yl)-4-(2-hydroxypropan-2-yl)benzamide Chemical compound C1=C2N(C)C=C(Cl)C2=CN=C1NC(=O)C1=CC=C(C(C)(C)O)C=C1 HZDQWXQRWFHBHB-UHFFFAOYSA-N 0.000 claims 1
- GVZZEAPBOBILMV-SFHVURJKSA-N n-(3-chloro-1-methylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2r)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=C2N(C)C=C(Cl)C2=CN=C1NC(=O)C1=CC=C([C@@](C)(O)CO)C=C1 GVZZEAPBOBILMV-SFHVURJKSA-N 0.000 claims 1
- GVZZEAPBOBILMV-GOSISDBHSA-N n-(3-chloro-1-methylpyrrolo[3,2-c]pyridin-6-yl)-4-[(2s)-1,2-dihydroxypropan-2-yl]benzamide Chemical compound C1=C2N(C)C=C(Cl)C2=CN=C1NC(=O)C1=CC=C([C@](C)(O)CO)C=C1 GVZZEAPBOBILMV-GOSISDBHSA-N 0.000 claims 1
- OFLQFDPYHCROCP-UHFFFAOYSA-N n-[1-(cyclopropylmethyl)pyrrolo[3,2-c]pyridin-6-yl]-4-(2-hydroxypropan-2-yl)benzamide Chemical compound C1=CC(C(C)(O)C)=CC=C1C(=O)NC(N=C1)=CC2=C1C=CN2CC1CC1 OFLQFDPYHCROCP-UHFFFAOYSA-N 0.000 claims 1
- MIIQFKVDBRZCLR-UHFFFAOYSA-N n-[3-bromo-1-(cyclopropylmethyl)pyrrolo[3,2-c]pyridin-6-yl]-4-(2-hydroxypropan-2-yl)benzamide Chemical compound C1=CC(C(C)(O)C)=CC=C1C(=O)NC(N=C1)=CC2=C1C(Br)=CN2CC1CC1 MIIQFKVDBRZCLR-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30086910P | 2010-02-03 | 2010-02-03 | |
| US61/300,869 | 2010-02-03 | ||
| PCT/US2011/022137 WO2011097079A1 (en) | 2010-02-03 | 2011-01-21 | Apoptosis signal-regulating kinase 1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518881A JP2013518881A (ja) | 2013-05-23 |
| JP2013518881A5 true JP2013518881A5 (enExample) | 2014-01-30 |
| JP5711270B2 JP5711270B2 (ja) | 2015-04-30 |
Family
ID=43645892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551994A Expired - Fee Related JP5711270B2 (ja) | 2010-02-03 | 2011-01-21 | アポトーシスシグナル調節キナーゼ１阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8802695B2 (enExample) |
| EP (1) | EP2531501B1 (enExample) |
| JP (1) | JP5711270B2 (enExample) |
| CN (1) | CN102834393B (enExample) |
| CA (1) | CA2787360C (enExample) |
| DK (1) | DK2531501T3 (enExample) |
| ES (1) | ES2445917T3 (enExample) |
| HR (1) | HRP20140114T1 (enExample) |
| PL (1) | PL2531501T3 (enExample) |
| PT (1) | PT2531501E (enExample) |
| RS (1) | RS53176B (enExample) |
| SI (1) | SI2531501T1 (enExample) |
| SM (1) | SMT201400012B (enExample) |
| WO (1) | WO2011097079A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| SI2531501T1 (sl) | 2010-02-03 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Inhibitorji kinaze-1, ki regulirajo signal apoptoze |
| MX2012015105A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
| JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ａｓｋ１阻害ピロロピリミジン誘導体 |
| AU2012301617A1 (en) | 2011-09-02 | 2014-04-17 | Salk Institute For Biological Studies | CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| RU2014149136A (ru) * | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| AU2014358668B2 (en) * | 2013-12-04 | 2019-10-24 | Galmed Research & Development Ltd. | Aramchol salts |
| TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
| MX2017003933A (es) | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| EP4276095A3 (en) | 2014-12-23 | 2024-01-17 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| US10849911B2 (en) | 2015-06-10 | 2020-12-01 | Galmed Research And Development Ltd. | Low dose compositions of Aramachol salts |
| JPWO2017169503A1 (ja) * | 2016-04-01 | 2019-02-14 | 国立大学法人千葉大学 | 含窒素芳香族アミドの製造方法、ピロール・イミダゾールポリアミドの製造方法、及び化合物 |
| EP3241830A1 (de) | 2016-05-04 | 2017-11-08 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| ES2938615T3 (es) | 2016-08-15 | 2023-04-13 | Bayer Cropscience Ag | Derivados del heterociclo bicíclico condensado como agentes de control de plagas |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| JOP20190221A1 (ar) * | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها |
| JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 |
| WO2018218044A2 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218042A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN110770233B (zh) * | 2017-06-19 | 2022-07-26 | 广东东阳光药业有限公司 | 稠合双环类化合物及其在药物中的应用 |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
| KR102798464B1 (ko) | 2018-05-02 | 2025-04-21 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나제 1 억제제를 포함하는 테트라졸 및 이의 사용 방법 |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US20210395241A1 (en) * | 2018-07-03 | 2021-12-23 | Novartis Ag | Nlrp modulators |
| CN113227070A (zh) * | 2018-08-14 | 2021-08-06 | 比奥根Ma公司 | Ask1抑制剂 |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) * | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CA3139809A1 (en) * | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
| KR20230127271A (ko) * | 2020-12-28 | 2023-08-31 | 셀진 코포레이션 | 헤테로시클릭 화합물 및 기생충성 질환을 위한 그의용도 |
| JP2025531844A (ja) * | 2022-09-08 | 2025-09-25 | ブリッジ メディシンズ | Ｅｎｌ／ａｆ９ ｙｅａｔｓ及びｆｌｔ３の阻害剤 |
| CN115368352B (zh) * | 2022-10-25 | 2023-08-15 | 南京盛德瑞尔医药科技有限公司 | 一种葡萄糖激酶激动剂及其制备方法和应用 |
| CN117122288B (zh) * | 2023-09-08 | 2024-10-18 | 太原理工大学 | 基于锚定卷积网络的癫痫脑电信号预警方法及装置 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US4062950A (en) | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| AU648523B2 (en) | 1989-10-25 | 1994-04-28 | Salk Institute For Biological Studies, The | Receptor infection assay |
| DE69129226T2 (de) | 1990-01-24 | 1998-07-30 | Douglas I. Woodside Calif. Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| JPH06503642A (ja) | 1990-09-21 | 1994-04-21 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | プロトオンコタンパク質ｃ−ＪＵＮとホルモン受容体との間の機能的拮抗作用 |
| DK0526171T3 (da) | 1991-07-30 | 1997-08-25 | Ajinomoto Kk | Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf |
| US5866563A (en) | 1991-09-30 | 1999-02-02 | The University Of British Columbia | Vanadium compositions |
| EP0619842A1 (en) | 1991-12-06 | 1994-10-19 | The Salk Institute For Biological Studies | Multimeric forms of members of the steroid/thyroid superfamily of receptors |
| ATE365209T1 (de) | 1992-05-14 | 2007-07-15 | Baylor College Medicine | Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie |
| CA2160135A1 (en) | 1993-04-07 | 1994-10-13 | Donald P. Mcdonnell | Method for screening for receptor agonists |
| US6074861A (en) | 1993-04-15 | 2000-06-13 | National Jewish Center For Immunology And Respiratory Medicine | MEKK proteins |
| US5981265A (en) | 1993-04-15 | 1999-11-09 | National Jewish Center For Immunology And Respiratory Medicine | Methods for regulating MEKK protein activity |
| US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
| EP0743520A3 (en) | 1993-12-30 | 1999-11-10 | The Salk Institute For Biological Studies | Novel uses for GAL4-receptor constructs |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| DE4416433A1 (de) | 1994-05-10 | 1995-11-16 | Hoechst Ag | Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten |
| US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| EP0832066B1 (en) | 1995-06-06 | 2001-09-12 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| CA2342471C (en) | 1995-06-06 | 2002-10-29 | Judith L. Treadway | Heterocyclecarbonylmethyl amine intermediates |
| WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| EP0859771A4 (en) | 1995-10-31 | 2000-03-15 | Merck & Co Inc | SUBSTITUTED PYRIDYLPYRROLE, PREPARATIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE USE THEREOF |
| AU2090897A (en) | 1996-02-29 | 1997-09-16 | Mikael Bols | Hydroxyhexahydropyridazines |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| JP3839103B2 (ja) | 1996-04-19 | 2006-11-01 | 財団法人癌研究会 | アポトーシス誘導タンパク質およびそれをコードする遺伝子 |
| EP1019043A4 (en) | 1996-05-07 | 2003-07-30 | Univ Pennsylvania | INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| ATE215369T1 (de) | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
| US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| FR2755439B1 (fr) | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
| JP2001504490A (ja) | 1996-11-20 | 2001-04-03 | メルク エンド カンパニー インコーポレーテッド | トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法 |
| EP0959885A4 (en) | 1996-11-20 | 2002-07-17 | Merck & Co Inc | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE |
| EP0959886A4 (en) | 1996-11-20 | 2001-05-02 | Merck & Co Inc | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS |
| US5880139A (en) | 1996-11-20 | 1999-03-09 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
| US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| EP0968209A1 (en) | 1997-01-28 | 2000-01-05 | Merck & Co., Inc. | THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| AU6290998A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| WO1999001423A1 (en) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| EP1017697A1 (en) | 1997-09-23 | 2000-07-12 | Novo Nordisk A/S | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| JP2001525398A (ja) | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | 選択的β３アドレナリン作動性アゴニスト |
| AU2610299A (en) | 1998-02-05 | 1999-08-23 | Novo Nordisk A/S | Hydrazone derivatives |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP1062218A1 (en) | 1998-03-12 | 2000-12-27 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| WO1999046236A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| CA2289621A1 (en) | 1998-03-16 | 1999-09-23 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase) |
| EP1073643B1 (en) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| CA2330555A1 (en) | 1998-05-12 | 1999-11-18 | Jay Edward Wrobel | Naphtho[2,3-b]heteroar-4-yl derivatives |
| US6057316A (en) | 1998-05-12 | 2000-05-02 | American Home Products Corporation | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes |
| ATE229015T1 (de) | 1998-05-12 | 2002-12-15 | Wyeth Corp | Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren |
| US6001867A (en) | 1998-05-12 | 1999-12-14 | American Home Products Corporation | 1-aryl-dibenzothiophenes |
| EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
| AU5154699A (en) | 1998-09-02 | 2000-03-27 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives |
| DE69910045T2 (de) | 1998-09-09 | 2004-04-22 | Metabasis Therapeutics Inc., San Diego | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren |
| WO2000021927A2 (en) | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Pyrrole-2,5-diones as gsk-3 inhibitors |
| GB9905416D0 (en) | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
| GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
| US6080546A (en) | 1999-07-23 | 2000-06-27 | Isis Pharmaceuticals Inc. | Antisense modulation of MEKK5 expression |
| US6030837A (en) | 1999-08-03 | 2000-02-29 | Isis Pharmaceuticals Inc. | Antisense inhibition of PEPCK-mitochondrial expression |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| EP1572720A4 (en) | 2002-05-24 | 2008-12-24 | Nps Allelix Corp | PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES |
| EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| JP2010536917A (ja) * | 2007-08-31 | 2010-12-02 | メルク セローノ ソシエテ アノニム | トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法 |
| EP2271646A1 (en) * | 2008-03-31 | 2011-01-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| SI2531501T1 (sl) * | 2010-02-03 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Inhibitorji kinaze-1, ki regulirajo signal apoptoze |
-
2011
- 2011-01-21 SI SI201130115T patent/SI2531501T1/sl unknown
- 2011-01-21 ES ES11701347.4T patent/ES2445917T3/es active Active
- 2011-01-21 DK DK11701347.4T patent/DK2531501T3/en active
- 2011-01-21 RS RS20140066A patent/RS53176B/sr unknown
- 2011-01-21 PT PT117013474T patent/PT2531501E/pt unknown
- 2011-01-21 HR HRP20140114AT patent/HRP20140114T1/hr unknown
- 2011-01-21 CN CN201180016037.8A patent/CN102834393B/zh not_active Expired - Fee Related
- 2011-01-21 CA CA2787360A patent/CA2787360C/en not_active Expired - Fee Related
- 2011-01-21 EP EP11701347.4A patent/EP2531501B1/en active Active
- 2011-01-21 PL PL11701347T patent/PL2531501T3/pl unknown
- 2011-01-21 JP JP2012551994A patent/JP5711270B2/ja not_active Expired - Fee Related
- 2011-01-21 WO PCT/US2011/022137 patent/WO2011097079A1/en not_active Ceased
- 2011-01-21 US US13/577,182 patent/US8802695B2/en not_active Expired - Fee Related
-
2014
- 2014-01-27 SM SM201400012T patent/SMT201400012B/xx unknown
- 2014-07-21 US US14/336,871 patent/US9403819B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518881A5 (enExample) | ||
| HRP20140114T1 (hr) | Inhibitori kinaze 1 koji reguliraju signal apoptoze | |
| CN104822680B (zh) | 咪唑并吡啶化合物 | |
| HRP20241159T1 (hr) | Heterociklički agonisti za glp-1 | |
| AU2015237788B2 (en) | ROR-gamma modulators and uses thereof | |
| JP2020529405A5 (enExample) | ||
| RU2019142795A (ru) | Производное n-(азаарил)циклолактам-1-карбоксамида, метод его получения и его применение | |
| CA2570942A1 (en) | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament | |
| KR20110069860A (ko) | 트라마돌 및 ＮＳＡＩＤｓ의 공결정 | |
| JP2017511794A5 (enExample) | ||
| JP2011500693A5 (enExample) | ||
| JP2008502614A5 (enExample) | ||
| CN106431993B (zh) | 一种lcz-696关键中间体的制备方法 | |
| WO2010059922A1 (en) | Pyrrolidine carboxamide compounds | |
| JPWO2014200075A1 (ja) | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| RU2014121394A (ru) | Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами | |
| TW202114985A (zh) | Ｅｐ拮抗劑 | |
| JP2011521964A5 (enExample) | ||
| WO2001010826A1 (en) | Substituted aromatic-ring compounds, process for producing the same, and use | |
| JP2015502371A5 (enExample) | ||
| TWI753929B (zh) | 吡咯啶衍生物 | |
| JP2023516714A (ja) | 新規ｅｐ４拮抗薬の合成及びその癌及び炎症における使用 | |
| WO2006111560A2 (en) | 2,3 substituted pyrazine sulfonamides as inhibitors of crth2 | |
| JP2008542365A5 (enExample) | ||
| RU2017131522A (ru) | (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота |